Amarin Corp Plcuk (AMRN) Change in Accured Expenses (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Change in Accured Expenses of -$14.8 million for Q1 2026, up 15.54% YoY from -$12.8 million in Q1 2025, and down 221.18% sequentially from $12.2 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Change in Accured Expenses across 17 years of filings, most recently posting -$14.8 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 15.54% year-over-year to -$14.8 million; the TTM figure through Mar 2026 stood at $17.2 million (up 128.9% YoY), while the FY2025 annual figure was $14.5 million, up 118.85% from the prior year.
- Change in Accured Expenses fell to -$14.8 million in Q1 2026, from $12.2 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for AMRN reached as high as $61.0 million in Q2 2022 and fell as low as -$69.7 million in Q1 2022.
- The 5-year median for Change in Accured Expenses is -$14.8 million (2026), against an average of -$10.6 million.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses sank 1175.14% — and 2025, when it surged 176.85%.
- A 5-year view of Change in Accured Expenses shows it stood at -$28.1 million in 2022, then soared by 73.09% to -$7.6 million in 2023, then tumbled by 186.16% to -$21.6 million in 2024, then soared by 156.59% to $12.2 million in 2025, then sank by 221.18% to -$14.8 million in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$14.8 million, $12.2 million, and -$3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -629.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -1.59 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -75.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -702.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | -14.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.82 Mn |
| Mar 31, 2026 | -14.82 Mn |
| Dec 31, 2025 | 12.23 Mn |
| Dec 31, 2025 | 12.23 Mn |
| Sep 30, 2025 | -3.71 Mn |
| Sep 30, 2025 | -3.71 Mn |
| Jun 30, 2025 | 23.54 Mn |
| Jun 30, 2025 | 23.54 Mn |
| Mar 31, 2025 | -17.54 Mn |
| Mar 31, 2025 | -17.54 Mn |
| Dec 31, 2024 | -21.61 Mn |
| Dec 31, 2024 | -21.61 Mn |
| Sep 30, 2024 | -28.99 Mn |
| Sep 30, 2024 | -28.99 Mn |
| Jun 30, 2024 | 8.50 Mn |
| Jun 30, 2024 | 8.50 Mn |
| Mar 31, 2024 | -34.90 Mn |
| Mar 31, 2024 | -34.90 Mn |
| Dec 31, 2023 | -7.55 Mn |
| Dec 31, 2023 | -7.55 Mn |